PT  - JOURNAL ARTICLE
AU  - Oshakbayev, Kuat
AU  - Durmanova, Aigul
AU  - Idrisov, Alisher
AU  - Zhankalova, Zulfiya
AU  - Bedelbayeva, Gulnara
AU  - Gazaliyeva, Meruyert
AU  - Tordai, Attila
AU  - Nabiyev, Altay
AU  - Dukenbayeva, Bibazhar
TI  - Weight loss in patients with COVID-19 and Influenza in comorbidity with NCDs: a pilot prospective clinical trial
AID  - 10.1101/2022.12.04.22283077
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.04.22283077
4099  - http://medrxiv.org/content/early/2022/12/06/2022.12.04.22283077.short
4100  - http://medrxiv.org/content/early/2022/12/06/2022.12.04.22283077.full
AB  - Background COVID and Influenza with non-communicable chronic diseases (NCDs) complicate the diagnosis, treatment, prognosis, and increase mortality rate. The aim: to evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID and Influenza in comorbidity with NCDs.Methods A 6-week open, pilot prospective clinical trial including 62 adult patients with COVID (n=27) and influenza (n=35) in comorbidity with T2D, hypertension, and NASH. Overweight in 33 patients (53.2%) with BMI 28.14±0.39 kg/m2, and 29 patients without overweight with BMI 23.37 ± 0.38 kg/m2. T2D in 26 (41.9%); Hypertension in 38 (61.3%) (incl. 12 patients with T2D); NASH in 51 patients (82.2%) (incl. 8 patients with NASH, T2D and Hypertension; 6 patients with NASH and T2D; 18 patients with NASH and Hypertension; 19 patients with only NASH). Primary endpoints: Clinic/infectious/inflammation tests for COVID and Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan.Results The patients with overweight lost -12,4% from baseline or BMI= -4.2 kg/m2, and patients without overweight lost -9,14% from baseline or BMI= -2.2 kg/m2 (−9.7±0.7 kg vs. - 6.4±0.6 kg, respectively; P<0.001) at 14-day of the treatment. Weight loss in both groups was due to reduction of fat mass (P<0.0001).Sputum production increased in 1.0-1.5 liter/day on 2-3 days, decreased in 7-9 days. Body temperature normalized in 6-9 days. On 3-5 days, in most patients their urine became turbid/muddy/intensively colored. Urine microscopy showed organic and non-organic salts, and leukocyturia (20-35/sight).White blood cells, lymphocytes, NLR normalized at 14 days (P<0.0001). Total-fibrinogen, C-reactive-protein, and Erythrocyte-sedimentation-rate, ROS normalized at 14-day of treatment (P<0.0001).COVID and Influenza were a negative in >96.3% patients at 14-day. Systolic/diastolic BP decreased (161.3±1.31/101.6±0.85 vs. 118.3±0.46/80.89±0.66, P<0.0001), glucose and lipids metabolism in patients with T2D (n=26) (P<0.0001); ALT and AST in patients with NASH (n=51) were significantly normalized (from baseline 134.3±5.4 and 166.5±5.5 U/L, respectively, and at 14-day to 78.4±4.2 and 92.4±4.9 U/L, respectively (P<0.0001)), platelets increased from baseline (186.5±4.6, ×109/L) at 14-day of treatment (238.5±5.8, ×109/L) (P<0.0001), and at 6-week follow-up (278.3±6.9, ×109/L) (P<0.0001). The mean score of chest-CT for the patients (n=44) was 13.12±0.38 from baseline, and at 14-day the score was 1.72±0.12 (P<0.0001). ROS level normalized at 14-day treatment and 6-week follow-up from baseline (P<0.0001). The previous antidiabetic, antihypertensive, anti-inflammatory and hepatoprotective, and other symptomatic medications were adequately decreased in 2-5 days to completely stopping by 5-8 days treatment.Conclusions The fast weight loss is clinical/laboratory benefit in treatment of patients with COVID-19 and Influenza in comorbidity with T2D, hypertension, and NASH.Trial Registration ClinicalTrials.gov NCT05635539. Registered 1 December 2022.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov NCT05635539Funding StatementNoAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local Ethics Committee of the University Medical Center (phone: +71272-692586 e-mails: mirgul.bayanova{at}umc.org.kz https://umc.org.kz/en/?ethics-commission) approved the study “The fast weight loss in patients with acute and chronic respiratory infections in comorbidity with non-communicable diseases” (approval protocol number is #7 of 26.09.2019).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFirst, the data is too large (> 2.8 GB). Secondly, we will make our data available to any investigator/reviewer on their own request, so that the personal privacy of our patients cannot be compromised.ALTalanine aminotransferaseANADETO‘Analimentary detoxication’ weight loss methodAOPPadvanced oxidation protein productsASTaspartate aminotransferaseBMIbody mass indexBPblood pressureCTComputed tomographyCOVIDSARS-CoV-2, a virus which causes the disease known as COVID-19HbA1cglycosylated hemoglobin A1cHDLhigh density lipoproteinHOMA-IRHomeostasis Model Assessment for Insulin ResistanceM±SDMean ± standard deviationM±SEMMean ± standard error of the meanMDAmalondialdehydeNASHNonalcoholic steatohepatitisNCDsnon-communicable chronic diseasesROSreactive oxygen speciesSODsuperoxide dismutaseT2Dtype 2 diabetes mellitus